Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation

• Status: Unknown status
• Trial end date: 2018-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to observe a new scheme can achieve is the same as the traditional scheme of the effect of preventing hepatitis B recurrence.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Third Affiliated Hospital, Sun Yat-Sen University
• Treatments: Antibodies; Entecavir; gamma-Globulins; Immunoglobulins; Immunoglobulins, Intravenous; Rho(D) Immune Globulin

Criteria

Inclusion Criteria:

1. correlation disease hepatitis B viral hepatitis liver transplantation recipients for the first time;

2. older than 18 years old, men and women not limited;

3. preoperative HbsAg positive, regardless of whether preoperative HBV DNA level, regardless of whether preoperative antiviral treatment, regardless of whether associated with primary liver cancer;

4. donor HbsAg negative, other virology negative in liver conditions;

5. to integrate research, good adherence.

Exclusion Criteria:

1. overlap other types of viral hepatitis;

2. the correlation of end-stage liver disease hepatitis b;

3. again to liver transplantation, or joint organ transplantation;

4. allergic to hepatitis b immune globulin;

5. of primary hepatocellular carcinoma with vena cava, portal vein around the trunk or branch, hepatic vein and other large vascular invasion;

6. ABO blood group incompatibility in liver transplantation;

7. moderately severe renal insufficiency, serum creatinine 180 umol/L or higher;

8. there has been a drug resistance of entecavir before liver transplantation.